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A B S T R A C T   
Background: As disease progression remains poorly understood in multiple sclerosis (MS), we aim to investigate 
the sequence in which different disease milestones occur using a novel data-driven approach. 
Methods: We analysed a cohort of 295 relapse-onset MS patients and 96 healthy controls, and considered 28 
features, capturing information on T2-lesion load, regional brain and spinal cord volumes, resting-state func-
tional centrality (“hubness”), microstructural tissue integrity of major white matter (WM) tracts and performance 
on multiple cognitive tests. We used a discriminative event-based model to estimate the sequence of biomarker 
abnormality in MS progression in general, as well as specific models for worsening physical disability and 
cognitive impairment. 
Results: We demonstrated that grey matter (GM) atrophy of the cerebellum, thalamus, and changes in cortico-
spinal tracts are early events in MS pathology, whereas other WM tracts as well as the cognitive domains of 
working memory, attention, and executive function are consistently late events. The models for disability and 
cognition show early functional changes of the default-mode network and earlier changes in spinal cord volume 
compared to the general MS population. Overall, GM atrophy seems crucial due to its early involvement in the 
disease course, whereas WM tract integrity appears to be affected relatively late despite the early onset of WM 
lesions. 
Conclusion: Data-driven modelling revealed the relative occurrence of both imaging and non-imaging events as 
MS progresses, providing insights into disease propagation mechanisms, and allowing fine-grained staging of 
patients for monitoring purposes   
1. Introduction 
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and 
neurodegenerative disease of the central nervous system (CNS) (Longo 
et al., 2018) frequently leading to physical disability and cognitive 
decline (Compston and Coles, 2008). The underlying pathological pro-
cesses result in tissue damage, leaving behind demyelinating lesions and 
white (WM) and grey matter (GM) atrophy that can be visualised and 
quantified by brain and spinal cord imaging (Dekker and Wattjes, 2017). 
Alterations in structural and functional networks of the brain also have 
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clear clinical relevance (Filippi et al., 2014). Usually considered in 
isolation, various studies have considered these features of MS. How-
ever, the sequence in which these changes occur remains unclear, in part 
due to scarcity of longitudinal data. 
Event-based modelling (EBM) is a probabilistic data-driven approach 
to study disease progression that uses cross-sectional data to estimate 
the temporal sequence of events and subsequently stage patients within 
this sequence (Fonteijn et al., 2012; Young et al., 2014). This type of 
model has been applied in Alzheimer’s disease (Fonteijn et al., 2012; 
Young et al., 2014; Oxtoby et al., 2018), Huntington’s disease (Fonteijn 
et al., 2012; Wijeratne et al., 2018), and a recent EBM study in MS pa-
tients provided insights into the sequence of GM atrophy, but did not 
include features derived from other modalities (Eshaghi et al., 2018). 
In the present study we go beyond the aspect of atrophy in MS and 
consider a broader set of structural, functional, and cognitive outcomes. 
We explored measures quantifying demyelination (focal WM lesions) 
(Compston and Coles, 2008), neurodegeneration (GM atrophy) (Bergs-
land et al., 2012), microstructural changes of WM tracts (fractional 
anisotropy) (Huang et al., 2018), and functional centrality of key brain 
networks (Filippi et al., 2014; Schoonheim et al., 2014) using a 
discriminative EBM (dEBM), which is more accurate and computation-
ally efficient than the original EBM implementation (Venkatraghavan 
et al., 2019). The imaging biomarkers were supplemented with mea-
sures of cognitive performance (Schoonheim et al., 2012). Our multi-
modal dEBM could improve the interpretation of studies using single 
biomarkers, provide useful insights into disease propagation mecha-
nisms, and aid in fine-grained staging and precise monitoring of pa-
tients. Therefore, the primary aim was to build a model that reflects a 
sequence of events in disease evolution in MS patients with a relapse 
onset. The secondary aim was to explore the event sequence for patients 
in relation to worsening physical and cognitive burden separately, 
because underlying disease processes could be different. 
2. Methods 
2.1. Participants 
In this retrospective analysis study, we included data from the 
Amsterdam MS cohort based on the availability of multimodal data, 
resulting in the inclusion of 96 healthy controls (HC) and 295 patients 
with relapse-onset MS (ROMS) according to the 2011 revisions of the 
McDonald criteria (Polman et al., 2011). Patients with a primary pro-
gressive disease onset have been excluded. 
The institutional ethics review board of the VU University Medical 
Center approved the protocol and written informed consent was ob-
tained from all participants prior to inclusion. 
2.2. Clinical assessments 
The Expanded Disability Status Scale (EDSS) score was assessed in all 
patients and was used to classify patients into three groups according to 
having minimal (EDSS 0.0 – 2.5), moderate (EDSS 3.0 – 3.5) or severe 
disability (EDSS ≥ 4.0) as defined in (Kurtzke, 1983). Cognitive per-
formance was assessed in all patients and HCs using an expanded Brief 
Repeatable Battery of Neuropsychological tests (Rao, 1990) with 
different cognitive domains tested, as described previously (Schoonheim 
et al., 2012). Raw test scores were corrected for the confounding effects 
of sex, age and education trends seen in the HCs (Amato et al., 2006). 
Cognitive domain-specific z-scores were calculated using the mean and 
standard deviation (SD) of the HCs. Patients were sub-divided into three 
cognitive-performance groups according to the z-scores obtained from 
the neuropsychological tests. Patients with z ≤ − 2 on at least 2 out of 7 
cognitive domains of the neuropsychological tests were labelled as 
cognitively impaired (CI), patients with z ≤ − 1.5 on at least 2 cognitive 
domains but not fulfilling CI criteria were classified as mildly cognitively 
impaired (MCI) and the remaining patients were classified as cognitively 
preserved (CP) (Schoonheim et al., 2015). Level of education was 
measured using a scale ranging from 1 (unfinished primary school) to 7 
(a university degree or higher) (Verhage and Van Der Werff, 1964). 
2.3. Magnetic resonance imaging 
A 3 Tesla whole-body MR system was used to scan all participants 
(GE Signa HDxt, Milwaukee, WI) using an 8-channel phased-array head 
coil. The scan protocol included a 3D T1-weighted fast spoiled gradient- 
echo sequence for volume measures (TR: 7.8 ms, TE: 3 ms, 240 × 240 
mm2 field of view (FOV), 176 sagittal slices of 1 mm thickness, 0.94 ×
0.94 mm2 in-plane resolution), a 3D fluid-attenuated inversion recovery 
(FLAIR) sequence for lesion detection (TR: 8000 ms, TE: 125 ms, TI: 
2350 ms, 250 × 250 mm2 FOV, 132 sagittal slices of 1.2 mm thickness, 
0.98 × 0.98 mm2 in-plane resolution), a diffusion-weighted imaging 
(DWI) sequence to detect microstructural changes in WM tracts (TR: 13 
s, TE: 86 ms, 2.4 mm contiguous axial slices, 2.0 × 2.0 mm2 in-plane 
resolution, 30 volumes with b-value = 900 s/mm2, 5 volumes with b- 
value = 0 s/mm2), and a whole-brain resting-state fMRI sequence to 
measure eigenvector centrality (functional centrality; (200 volumes, TR: 
2200 ms, TE: 35 ms, 3 mm contiguous axial slices covering the entire 
brain, 3.3 × 3.3 mm2 in-plane resolution)). FLAIR images were generally 
only acquired for patient, not HCs. More details on the protocol can be 
found in a previous report on this cohort (Eijlers et al., 2018). 
FLAIR images were used to segment WM lesions in MS patients using 
a k-Nearest-Neighbours approach with tissue type priors (kNN-TTP) 
(Steenwijk et al., 2013). Lesion maps were registered to 3D T1-weighted 
images and filled using a validated patch-based approach (Prados et al., 
2016). 
Brain parcellation of cortical and subcortical regions was obtained 
using geodesic information flows (GIF) (Cardoso et al., 2015) on the 3D 
T1-weighted MRI scans, a method that has been used previously in ap-
plications of MS (Eshaghi et al., 2018; Pardini et al., 2016), including a 
predecessor study on EBM-based atrophy progression (Eshaghi et al., 
2018), and other neurological disorders (Ingala et al., 2020), as well as a 
pre-processing tool for segmenting WM hyperintensities (Sudre et al., 
2017). GIF is an atlas-propagation-based method that registers T1 scans 
of 160 subjects with manually delineated brain structures to each target 
scan, then identifies the closest local matches and uses those matches for 
segmentation. The atlas segmentations are based on the Desikan- 
Killiany-Tourville protocol, which was designed to improve accuracy 
and consistency of brain labels compared to the classic Desikan-Killiany 
atlas database (Klein and Tourville, 2012). To further quantify regional 
lesion loads, the white matter was initially divided into 10 concentric 
bands between the ependyma of the ventricles and the pial surface based 
on normalized subject-specific distance maps derived from Laplace 
equation isolines (Pardini et al., 2016; Sudre et al., 2018). The bands 
were then grouped as inner (band 1–2), intermediate deep (band 3–8), 
and outer bands (band 9–10) to in order to obtain a data-driven 
approximation of the stratification used in (pre-)clinic. Infratentorial 
lesions were subsequently discarded because they were only present in a 
small subset of patients. 
Spinal cord atrophy was quantified as mean upper cervical cord area 
(MUCCA) using SCT-PropSeg (De Leener et al., 2014). Analyses were 
performed on the 3D T1-weighted images of the brain, which cover a 
sufficient length of the cervical spinal cord. We measured over a length 
of 30 mm along the central canal, starting at the top of the second cer-
vical vertebra, C2. MUCCA measurements on brain images have been 
shown to be as reproducible as those performed on dedicated spinal cord 
MRI (Lukas et al., 2018; Liu, 2016). 
Functional MRI processing steps for obtaining eigenvector centrality 
maps (ECM) have been published previously (Eijlers et al., 2017). The 
MELODIC pipeline (part of FSL (Smith et al., 2004), using standard 
settings) was used to process resting-state fMRI images, followed by 
nonlinear registration to Montreal Neurological Institute standard 
space, and resampling to a resolution of 4 mm isotropic. The MELODIC 
I. Dekker et al.                                                                                                                                                                                                                                   
NeuroImage: Clinical 29 (2021) 102550
3
outcomes were further processed using fastECM (Wink et al., 2012) to 
estimate voxel-wise eigenvector centrality as a network measure of 
functional hubness (brain function) in the default-mode network 
(DMN), basal ganglia and sensorimotor network. 
DWI scans were pre-processed using FSL5, including motion- and 
eddy current correction on images and gradient vectors, followed by 
diffusion tensor fitting for diffusion tensor imaging (DTI). The resulting 
fractional anisotropy (FA) maps were then fed into the tract-based 
spatial statistics (TBSS) pipeline (Meijer, 2018), after which the skel-
eton was masked using the JHU white-matter tractography atlas from 
FSL to define WM tracts (Mori, 2005). 
There was only a minor amount of motion artefacts present in the 
advances imaging sequences, and we did not observe any difference in 
artefact severity between groups. 
2.4. Discriminative event-based model 
The EBM uses cross-sectional data to estimate the ordered sequence 
of cumulative abnormality in a disease, together with uncertainty in the 
ordering. Here, we used the discriminative EBM (dEBM; https://github. 
com/EuroPOND/pyebm) described previously as it has been shown to 
be more accurate and computationally efficient compared to other EBM 
implementations (Venkatraghavan et al., 2019, 2017). The dEBM esti-
mates the probability for each biomarker being normal or abnormal 
using a Gaussian mixture model (GMM) based on data from a disease 
and a reference population. Based on the probability distributions of the 
biomarkers in the two groups, an individual sequence of biomarker 
abnormality is calculated for each patient. Finally, these individual se-
quences are combined statistically to give an ordering for the whole 
population (Venkatraghavan et al., 2019). The uncertainty of this 
ordering is estimated by bootstrapping, i.e. repeating the experiment 
with random subsets of subjects. Subjects can be staged within the event 
sequence by identifying the events that have already become abnormal 
for each individual subject (Young et al., 2014). 
2.5. Selected biomarkers 
We included multimodal biomarkers with relevance in MS whilst 
limiting the overall number of features in the model to allow for better 
interpretability of results and faster computation. The following 28 MS- 
related biomarkers were considered (before statistical post-selection as 
described below): 
GM volumes of the thalamus, hippocampus, basal ganglia (without 
thalamus and hippocampus), cerebellar GM, cingulate, frontal lobe, 
insula, occipital lobe, parietal lobe and temporal lobe. These regions 
cover the entire brain to allow for a rough estimate of the general at-
rophy sequence. 
MUCCA was included for all subjects as an indicator of spinal cord 
volume. 
T2-hyperintense lesion loads on FLAIR images were considered only 
for patients and split according to the inner (i.e., periventricular), outer 
(i.e., juxtacortical) and intermediate deep WM bands in order to obtain a 
data-driven approximation of the stratification used in (pre-)clinic. 
Functional centrality in the default mode network (DMN), sensori-
motor cortex network and basal ganglia network; the voxelwise ECM- 
measures were averaged within the respective anatomical regions. The 
selected networks are linked to MS progression in the domains cognition 
(Eijlers et al., 2017), fatigue (Finke, 2015) and clinical recovery (Mez-
zapesa et al., 2008). 
Microstructural changes of WM tracts measured by fractional anisotropy 
(FA) in 3 major WM tracts related to cognition (anterior thalamic ra-
diation and cingulum (Eijlers, 2018; Koenig, 2015) and motor function 
(corticospinal tract (Reich et al., 2007) and all other WM tracts com-
bined (forceps minor, forceps major, inferior fronto-occipital fasciculus, 
inferior longitudinal fasciculus, superior longitudinal fasciculus, and 
uncinate fasciculus); the voxelwise FA-measures were averaged within 
the respective anatomical regions. 
Cognitive function by cognitive domain: executive function, verbal 
memory, information processing, verbal fluency, visuospatial, working 
memory and attention. 
2.6. Statistics 
Normality of data was checked by visual inspection of histograms 
combined with Kolmogorov-Smirnov testing. Parametric (independent- 
samples t-test) and non-parametric (Mann-Whitney U test and chi- 
square test) tests were used to compare groups () for demographic, 
clinical and imaging characteristics (Table 1, 2 and 3). All measures, 
except lesions, which could only be obtained in patients, were corrected 
for the confounding effects of age, sex and education seen in HCs using 
one linear regression model per biomarker. The residuals of these fits 
were then transformed into z-scores using the mean and SD from HCs. 
We used SPSS 22.0 and 24.0 (IBM Corp., Armonk, NY, USA) and the 
scipy python package (version 1.2.1) for statistical analyses. The level of 
significance for demographic and clinical data (Table 1, 2 and 3) was set 
at p < 0.05. 
2.7. Model fitting 
The dEBM relies on a Gaussian Mixture of the biomarker distribu-
tions, and requires a sufficient separation of the respective distributions 
from the control and disease groups. Therefore, we performed a 
biomarker post-selection and included only those biomarkers that 
passed a two-sided independent samples t-test at a significance level of p 
≤ 0.1. We used 1000 bootstraps sampled from the same cohort in order 
to estimate the positional variance of the event sequence. Individual 
subjects were finally staged within the model between stage 0 (no 
abnormal biomarkers) and stage N (all N biomarkers are abnormal). 
Three dEBMs were built to characterize the structural, functional, 
and cognitive changes in ROMS progression generally (Model 1), and 
specifically for disability worsening (Model 2) and cognitive decline 
(Model 3).  
• Model 1: Event sequence in all ROMS patients as a progression from 
HC.  
• Model 2: Event sequence in ROMS patients progressing from low 
(EDSS 0.0 – 2.5) to high disability level (EDSS ≥ 4.0). Intermediate 
patients with an EDSS of 3.0 or 3.5 were excluded from the GMM 
initialisation but used to estimate the event sequence. HCs were 
excluded for this analysis.  
• Model 3: Event sequence in MS patients progressing from cognitively 
preserved (CP) to cognitively impaired (CI). Patients with mild 
cognitive impairment (MCI) were excluded from the GMM initiali-
sation but used to estimate the event sequence. HCs were excluded 
for this analysis. 
3. Results 
At the time of data acquisition, 243 of ROMS patients were diagnosed 
with relapsing-remitting MS (RRMS) and 52 patients with secondary 
progressive MS (SPMS). The average age was 46.7 (standard deviation 
11.0) years and patients had their symptom onset 12.6 ± 1.6 years prior 
to assessment. The proportion of women was higher in the patient group 
(71.5%) than in HCs (58.3%, p = 0.016) and HCs had a higher educa-
tional level (p = 0.017). The median EDSS was 3.0 (IQR 2 – 4) with 120 
patients having low disability (EDSS 0.0 – 2.5) and 102 patients having 
high disability (EDSS ≥ 4.0). Seventy-five patients were cognitively 
impaired (CI), 52 patients were classified as MCI and 168 patients as CP 
(Fig. 1). Demographics and MRI metrics of patients and HCs are shown 
in Table 1. For the MRI measures, only two functional networks (DMN 
and basal ganglia) were not significantly different between patients and 
healthy controls after correction for confounding variables. 
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Biomarker post-selection resulted in 21, 25, and 17 biomarkers 
included in the final models 1 (general MS progression), 2 (disability in 
MS) and 3 (cognitive decline in MS), respectively. 
We visualize the models using positional variance diagrams (PVD; 
see Figs. 2, 4 and 6). The positional variance diagram shows the most 
likely sequence of events on the y-axis, while the x-axis represents the 
event position within the sequence ranging from one to the number of 
events. The intensity of each field represents the number of bootstraps 
where an event appeared at that respective position. This indicates un-
certainty in the sequence, such that a strong confidence in the ordering 
results in a dark diagonal in the positional variance diagram. 
3.1. Model 1: Sequence of events in relapse-onset multiple sclerosis 
progression 
The PVD of Model 1 is shown in Fig. 2. Despite considerable uncer-
tainty, ROMS tends to starts with decreases in the corticospinal tract FA 
as well as cerebellar and thalamic atrophy. Neurodegeneration con-
tinues to involve the occipital and parietal lobes (position 5 and 7 of 21), 
through the temporal lobe, spinal cord (MUCCA) and basal ganglia 
(position 10, 12 and 13 of 21), with the cingulate and insula being 
affected later (position 16–17 of 21). Deficiency in visuospatial cogni-
tion is the earliest cognitive abnormality at position 4, shortly after 
thalamic atrophy, followed by verbal fluency, verbal memory and in-
formation processing (position 6, 9 and 11 of 21). Other cognitive do-
mains are estimated to be affected later. FA changes of the cingulum and 
the non-specific WM-tracts appear in the last third of the event sequence 
between the basal ganglia and the cingulate volume events. Anterior 
thalamic radiation FA becomes abnormal late (position 18 of 21). 
The staging reveals that healthy controls are mostly placed at earlier 
stages and no HC being staged higher than stage 11 of 21 (median stage 
2, mean stage 3) while ROMS patients are spread across all stages with a 
median stage of 8 (mean 9.4) as shown in Fig. 3. 
The effect on leaving out individual biomarkers or groups of bio-
markers from a certain modality is very small as shown qualitatively in 
the Supplementary Materials. 
The PVD for the main tracts of the JHU WM tractography atlas is 
shown in Figure S4. 
3.2. Model 2: Sequence of events in the progression of low-to-high 
disability in ROMS 
Table 2 shows the comparison between patients with high disability 
(EDSS of 4.0 or higher, n = 102) and patients with low disability (EDSS 
of 2.5 or lower, n = 120). Patients with high disability were older 
(average 53.1 versus 41.0 years, p < 0.001), had longer symptom 
duration (average 18.8 versus 10.6 years, p < 0.001), had a lower level 
of education (5 versus 4, p = 0.001), and a higher percentage of 
cognitive impairment (47.1% versus 13.3%, p < 0.001) than patients 
with low disability. Not all MRI measures showed significant differences 
(p < 0.1 was accepted in the biomarker post-selection) between patients 
with high versus low disability. The included markers are listed in Fig. 4. 
The sequence for progression from low to high disability is shown in 
Fig. 4. Insular and cerebellar GM atrophy occur early in the event 
sequence together with changes in centrality of the default-mode and 
basal-ganglia networks, and visuospatial perception (position 1–5 of 
25). Atrophy continues to occur in the thalamus, temporal lobe, MUCCA, 
parietal lobe, basal ganglia, while occipital and frontal lobe atrophy 
occur relatively late (position 19 and 21 of 25 respectively). Lesion load 
becomes abnormal first in the inner (periventricular) regions, then in the 
deep WM and the outer regions (i.e. juxtacortical). Changes in the FA 
biomarkers appear in the last third of the sequence, and cognitive 
Table 1 
Clinical and imaging measures, patients and healthy controls.  
Clinical measures Patients (n 
¼ 295) 
Healthy controls 
(n ¼ 96) 
p-value  
Age [years] * 47.0 ± 10.7 45.9 ± 10.4 0.37 a  
Sex [female, %] ** 211 (71.5) 56 (58.3) 0.016b  
Education level *** 5 (4 – 6) 6 (4 – 7) 0.017c  
Symptom duration [years] 
* 
12.6 ± 1.6 N/A –  
DMT ever used [%]** 173 (58.6) N/A –  
EDSS *** 3.0 (2.0 – 4.0) N/A –  
CP/MCI/CI [%] ** 25.4 / 17.6 / 
56.9 
N/A –  
RRMS/SPMS 243/52 N/A –  
Information processing 
speed [z-score] * 
− 1.12 (1.4) 0.0 (1.0) <0.001a  
Executive functioning [z- 
score] * 
− 0.95 (1.7) 0.0 (0.8) <0.001a  
Working memory [z-score] 
* 
− 1.02 (1.5) 0.0 (0.9) <0.001a  
Verbal memory [z-score] * − 0.48 (1.2) 0.0 (0.9) <0.001a  
Verbal fluency [z-score] * − 0.44 (1.1) 0.0 (1.0) <0.001a  
Visuospatial memory [z- 
score] * 
− 0.61 (1.2) 0.0 (0.9) <0.001a  
Attention [z-score] * − 0.65 (1.1) 0.0 (0.7) <0.001a 
MRI measures    
T2-hyperintense lesion loads [mL] 
*     
Total T2-hyperintense 
lesion load 
14.2 (12.7) N/A –  
Inner lesions 4.3 (3.3) N/A –  
Deep lesions 6.5 (6.9) N/A –  
Outer lesions 3.4 (3.5) N/A –  
Infratentorial 0.02 (0.04) N/A – 
Brain and spinal cord volumes 
[mL] *     
Total brain volume 1135.3 
(110.3) 
1181.8 (128.8) <0.001 
a  
Basal Ganglia 34.3 (3.5) 36.7 (4.1) <0.001 
a  
Hippocampus 7.6 (0.7) 8.0 (0.8) <0.001 
a  
Thalamus 10.1 (1.0) 11.7 (1.4) <0.001 
a  
Cingulate 27.7 (3.3) 29.0 (3.6) 0.002 a  
Frontal lobe 179.92 (18.8) 185.1 (20.8) 0.224 a  
Insula 10.7 (1.2) 11.3 (1.4) <0.001 
a  
Occipital lobe 66.6 (8.0) 70.3 (8.2) <0.001 
a  
Parietal lobe 91.1 (10.2) 95.0 (9.6) 0.002 a  
Temporal lobe 128.0 (13.4) 132.8 (15.0) 0.006 a  
Cerebellar grey matter 94.6 (9.5) 99.0 (10.1) 0.003 a  
MUCCA 64.7 (7.8) 68.6 (5.7) <0.001 
a 
Functional hubness (EC [z- 
scores])     
Basal ganglia network − 0.128 (0.23) 0 (0.26) 0.371 a  
Default mode network 0.009 (0.21) 0 (0.22) 0.755 a  
Sensorimotor cortex 
network 
− 0.046 (0.22) 0 (0.22) 0.234 a 
White matter tract integrity (FA 
[0–1])     
Anterior thalamic 
radiation 
0.453 (0.035) 0.479 (0.027) <0.001 
a  
Corticospinal tract 0.653 (0.028) 0.668 (0.028) <0.001 
a  
Cingulum 0.564 (0.047) 0.598 (0.041) <0.001 
a  
Other WM tracts 0.525 (0.035) 0.561 (0.026) <0.001 
a 
* Mean (standard deviation), ** number (percentage), *** median (IQR). a 
Independent-samples t-test, b chi-square test, c Mann-Whitney U test. CI: 
cognitively impaired; CP: cognitively preserved; DMT: disease modifying 
treatment; EC: eigenvector centrality; EDSS: expanded disability status scale; FA: 
fractional anisotropy; MCI: mild cognitively impaired; MUCCA: mean upper 
cervical cord area; N/A: not applicable. 
Table 1 shows the clinical and imaging measures of patients and healthy con-
trols. The p-values of the MRI measures are based on the z-scored comparisons. 
Biomarkers with a p-value < 0.1 were included in the model. 
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changes in attention, working memory and executive function are last to 
become abnormal. 
The patient staging shows that ROMS patients with all levels of 
disability can be found in all 25 stages (see Fig. 5). However, there is a 
clear trend such that patients with low EDSS have a median stage of 4 
(mean 6.9), patients with medium disability have a median stage of 6 
(mean 9.3), and patients with a high level of disability have a median 
stage of 16 (mean 14.6). 
3.3. Model 3: Sequence of events in ROMS as cognition declines 
All 295 patients had complete cognitive tests: 75 patients were 
classified as CI, 52 as MCI, and 168 patients as CP. Patients with CI were 
older (average 50.4 versus 45.7 years; p = 0.001), had a longer symptom 
duration (average 17.6 versus 13.3 years, p < 0.001), had a lower 
educational level (4 versus 6, p < 0.001) and a higher EDSS score 
(median 4.0 versus 3.0; p < 0.001), see Table 3 for the comparisons 
between CI and CP patients. 
The ordering of events in the dEBM of cognitive impairment is shown 
in Fig. 6. Similar to Model 2, the progression in cognitive decline is 
accompanied by early insular atrophy and increased functional DMN 
centrality. The event sequence continues with atrophy of the hippo-
campus, cervical cord, frontal, parietal, occipital and temporal lobes, 
and the thalamus (position 3–9 of 17) and finally the basal ganglia 
(position 14 of 17). Lesion events occur in close succession after most 
atrophy measures (position 10–12 of 17). Changes in WM tract FA occur 
at the end with the corticospinal tract being affected earlier than the rest 
(position 13 of 17). 
As in Model 2, all three groups are spread across all stages (see 
Fig. 7). Cognitively preserved ROMS patients have a median stage of 5 
(mean 5.3), patients with MCI have a median stage of 7.5 (mean 7.8), 
and cognitively impaired patients have a median stage of 12 (mean 
11.4). 
4. Discussion 
Current understanding of disease progression in MS is largely based 
on studies that each considered a small number of MS pathology features 
in isolation. This body of work has identified lesion number and loca-
tion, regional atrophy, changes in functional centrality of brain net-
works, or alterations in WM tract microstructure as features of interest. 
Until now, the sequence of accumulated abnormality in these bio-
markers relative to each other remained largely undetermined. Our 
data-driven dEBM analysis suggests that changes of the corticospinal 
tract, and GM volume changes of cerebellum, thalamus and occipital 
lobe are early events; whereas microstructural changes in other WM 
tracts and changes in cognitive domains attention, executive function 
and working memory are relatively late events in MS progression. We 
also estimated sequences specific to disability worsening and cognitive 
impairment motivated to reveal new insight into the underlying mech-
anisms of each, and to provide a quantitative template for patient 
Table 2 
Demographics high vs low EDSS.  
Clinical measures Total(n ¼
222) 
EDSS ≤ 2.5 
(n ¼ 120) 
EDSS ≥ 4.0 
(n ¼ 102) 
p-value 
Age [years]* 46.5 
(10.6) 
41.0 (8.5) 53.1 (8.9) <0.001a 
Sex [female, %]** 160 (72.1) 87 (72.5) 73 (71.6) 0.88b 
Education level [median, 
IQR]*** 
5 (4 – 6) 5 (4 – 6) 4 (3 – 6) 0.001c 
Symptom duration 
[years]* 
14.4 (8.4) 10.6 (5.7) 18.8 (8.8) <0.001a 
DMT used** 126 (56.8) 67 (55.8) 59 (57.8) 0.76b 
EDSS*** 2.5 (2.0 – 
4.5) 
2.0 (1.5 – 
2.5) 
5.0 (4.0 – 
6.0) 
<0.001c 
CP/MCI/CI [%]*** 53.6 / 
17.6 / 
28.8 
68.3 / 18.3 
/ 13.3 
36.3 / 16.7 
/ 47.1 
<0.001b 
RRMS/SPMS 176 / 46 119 / 1 57 / 45 <0.001b 
Information processing 
speed [z-score] * 
− 1.18 
(1.4) 
− 0.67 (1.2) − 1.80 (1.4) <0.001a 




− 0.50 (1.0) − 1.71 (2.4) <0.001a 




− 0.51 (1.0) − 1.69 (1.6) <0.001a 




− 0.25 (1.0) − 0.70 (1.2) 0.002a 
Verbal fluency [z-score] * − 0.52 
(1.1) 
− 0.22 (1.0) − 0.86 (1.0) <0.001a 




− 0.28 (1.1) − 1.04 (1.2) <0.001a 
Attention [z-score] * − 0.66 
(1.1) 
− 0.39 (0.9) − 0.98 (1.3) <0.001a 
MRI measures     
T2-hyperintense lesion 






11.2 (9.0) 18.9 (15.9) <0.001a  
Inner lesions 4.3 (3.3) 3.6 (2.5) 5.2 (3.8) <0.001a  
Deep lesions 6.9 (7.4) 5.1 (4.9) 9.1 (9.2) <0.001a  
Outer lesions 3.5 (3.4) 2.6 (2.3) 4.6 (4.1) <0.001a  
Infratentorial 0.01 
(0.04) 
0.01 (0.03) 0.02 (0.04) 0.31 a 
Brain and spinal cord 
volumes [mL] *      







Basal Ganglia 34.2 (3.6) 34.9 (3.6) 33.3 (3.5) <0.001a  
Hippocampus 7.6 (0.7) 7.7 (0.8) 7.4 (0.7) 0.011 a  
Thalamus 10.1 (1.5) 10.6 (1.3) 9.4 (1.3) <0.001a  
Cingulate 27.7 (3.3) 28.1 (3.2) 27.2 (3.4) 0.04 a  







Insula 10.7 (1.3) 11.0 (1.3) 10.3 (1.2) <0.001a  
Occipital lobe 66.3 (8.0) 68.3 (7.8) 64.0 (7.7) <0.001a  
Parietal lobe 91.1 
(10.2) 
94.0 (10.2) 87.8 (9.3) <0.001a  









94.3 (9.7) 96.6 (9.3) 91.6 (9.5) <0.001a  
MUCCA 64.5 (8.3) 65.6 (8.3) 63.2 (8.2) 0.07 a 
Functional hubness (EC [z- 




























White matter tract integrity 





0.47 (0.02) 0.44 (0.04) <0.001a  
Corticospinal tract 0.65 
(0.03) 
0.66 (0.02) 0.64 (0.03) <0.001a  
Cingulum 0.58 (0.04) 0.55 (0.05) <0.001a  
Table 2 (continued ) 
Clinical measures Total(n ¼
222) 
EDSS ≤ 2.5 
(n ¼ 120) 
EDSS ≥ 4.0 




Other WM tracts 0.53 
(0.04) 
0.54 (0.03) 0.51 (0.04) <0.001a 
* Mean (standard deviation), ** number (percentage), *** median (IQR). a 
Independent-samples t-test, b chi-square test, c Mann-Whitney U test. 
CI: cognitively impaired; CP: cognitively preserved; DMT: disease modifying 
treatment, EDSS: expanded disability status scale, IQR: interquartile range, MCI: 
mild cognitively impaired. 
Table 2 shows the clinical measures of the patient group split into low and higher 
EDSS. 
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assessment. The results of this secondary analysis suggest that functional 
network centrality of the default mode network is involved early in both, 
with DTI-related WM tract abnormality occurring later. 
4.1. Model 1: Sequence of events in relapse-onset multiple sclerosis 
progression 
The general ROMS model suggests that cerebellar atrophy is an early 
event. Although studies in patients with a clinically isolated syndrome 
(CIS) have not been conclusive on the presence of early cerebellar vol-
ume loss (Parmar, 2018), a recent EBM study in MS patients also showed 
cerebellar atrophy as part of the atrophy sequence (Eshaghi et al., 2018). 
Early thalamic and hippocampal atrophy in our study are in accordance 
with findings in previous studies reporting atrophy in these areas 
already in CIS patients (Audoin, 2010; Henry, 2008). Insular and 
cingulate atrophy occur relatively late in our study but the bootstrap 
analysis shows a bimodal distribution for these biomarkers with clusters 
at the beginning and the end of the sequence (see Fig. 2), which might 
indicate heterogeneity in the population such that some patients have 
the event early whereas others experience this later. Among the volu-
metric measurements, MUCCA abnormality occurs at an intermediate 
position in the event ordering, while previous literature indicates that 
spinal cord atrophy can be seen already in CIS patients on a group level 
and with high clinical relevance (Biberacher, 2015). This could be due to 
differences in measurement sensitivity or cohort size and requires 
further study. 
A second marker of white matter abnormality, the FA of the corti-
cospinal tract, appears as the first event, which agrees with previous 
Table 3 
Demographics cognitive preserved vs cognitive impaired  









Age [years]* 47.1 
(10.6) 
45.7 (10.3) 50.4 (10.5) 0.001a 
Sex [female, %]** 174 
(71.6) 
125 (74.4) 49 (65.3) 0.15b 
Education level 
[median, IQR]*** 





13.3 (7.7) 17.6 (9.6) <0.001a 
DMT used** 141 
(58.0) 
96 (57.1) 45 (60.0) 0.68b 
EDSS*** 3.0 (2.0 
– 4.0) 
3.0 (2.0 – 3.5) 4.0 (3.0 – 
6.0) 
<0.001c 
RRMS/SPMS 197 / 46 148 / 20 49 / 26 <0.001b 
Information processing 
speed [z-score] * 
− 1.01 
(1.4) 





− 0.19 (0.8) − 2.73 (2.3) <0.001a 




− 0.39 (0.8) − 2.40 (2.0) <0.001a 




0.02 (0.9) − 0.15 (1.1) <0.001a 









− 0.14 (1.0) − 1.49 (1.1) <0.001a 
Attention [z-score] * − 0.60 
(1.2) 
− 0.22 (0.7) − 1.48 (1.6) <0.001a 
MRI measures     
T2-hyperintense lesion 






10.3 (8.4) 21.4 (17.0) <0.001a  
Inner lesions 4.1 (3.2) 3.3 (2.3) 5.9 (4.0) <0.001a  
Deep lesions 6.3 (7.2) 4.6 (4.5) 10.3 (10.0) <0.001a  
Outer lesions 3.3 (3.3) 2.4 (2.1) 5.3 (4.4) <0.001a  
Infratentorial 0.01 
(0.04) 
0.01 (0.04) 0.01 (0.03) 0.95 a 
Brain and spinal cord 










Basal Ganglia 34.3 
(3.5) 
34.9 (3.3) 33.0 (3.7) <0.001a  
Hippocampus 7.6 (0.7) 7.7 (0.7) 7.5 (0.8) 0.02 a  
Thalamus 10.1 
(1.5) 
10.5 (1.3) 9.2 (1.5) <0.001a  
Cingulate 27.6 
(3.3) 
27.8 (3.3) 27.3 (3.3) 0.256 a  
Frontal lobe 180.4 
(19.2) 
182.9 (19.1) 174.8 (18.4) 0.002 a  
Insula 10.7 
(1.3) 
10.9 (1.3) 10.2 (1.1) <0.001a  
Occipital lobe 66.9 
(8.3) 
68.3 (8.1) 63.9 (8.0) <0.001a  
Parietal lobe 91.3 
(10.6) 
92.5 (10.6) 88.7 (10.1) 0.01 a  
Temporal lobe 128.2 
(13.5) 





95.4 (9.5) 92.6 (9.1) 0.031a  
MUCCA 64.5 
(7.9) 
65.7 (7.6) 61.6 (8.0) 0.001a 
Functional hubness (EC 



























0.600 a      
Table 3 (continued ) 









White matter tract 










0.66 (0.03) 0.64 (0.03) 0.002 a  
Cingulum 0.56 
(0.05) 
0.58 (0.04) 0.54 (0.06) <0.001a  
Other WM tracts 0.53 
(0.04) 
0.54 (0.03) 0.50 (0.05) <0.001a 
* Mean (standard deviation), ** number (percentage), *** median (IQR). a 
Independent-samples t-test, b chi-square test, c Mann-Whitney U test. 
CI: cognitively impaired; CP: cognitively preserved; DMT: disease modifying 
treatment, EDSS: expanded disability status scale, IQR: interquartile range, MCI: 
mild cognitively impaired. 
Table 3 shows the clinical measures of the patient group split into cognitively 
preserved and cognitively impaired. 
Fig. 1. Overview of diagnostic groups, and separation of ROMS subgroups.  
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work (Biberacher, 2015). In addition, research found that WM changes 
occur early in the disease (Huang et al., 2018), whereas most FA markers 
other than corticospinal tract damage included in this study were late 
events in the model. A probable explanation could be that the WM 
damage from lesions within the tracts is relatively small compared to 
overall sizes of the tract ROIs, so that the tract features mainly represent 
normal-appearing WM and hence have little disease signal. Additionally, 
there is substantial inter-patient heterogeneity in the anatomical dis-
tribution of WM damage, which creates an unclear relation between 
microstructural changes in specific WM tracts and progression along the 
disease course. 
The seven included cognitive domains are spread across the pro-
gression timeline but previous literature does not provide many concrete 
indications regarding the true positioning of those biomarkers given the 
lack of longitudinal data. However, the domains attention, executive 
function, and working memory were consistently late events in our 
analyses, which is supported by previous research (Meijer, 2016). 
Overall, we showed that the obtained event sequence is well in line with 
previous work on individual features but provides additional insight in 
the relative positioning of the multimodal features. The obtained 
sequence can potentially be used to stage patients within the disease 
course and help with clinical monitoring of disease progression beyond 
relapses and physical disability. However, the relatively high uncer-
tainty limits use for individual patients at this stage. 
4.2. Model 2: Sequence of events in the progression of low-to-high 
disability in relapse-onset multiple sclerosis 
The model for progression from low disability to high disability has 
many similarities to the general MS event sequence (Model 1) such as 
the early occurrence of cerebellar atrophy or visuospatial memory 
impairment, and the late events for white matter tract FA and the 
cognitive domains of attention, working memory and executive func-
tion. This is somewhat expected as minor impairment starts early in the 
disease course when brain structure is most similar to healthy controls. 
The most notable difference with Model 1 is the early increase of 
eigenvector centrality of the DMN and basal ganglia functional network, 
which supports findings on functional centrality as a correlate of phys-
ical disability (Schoonheim et al., 2014). Similarly, basal ganglia atro-
phy appears early in Model 2, supporting recent findings of deep GM 
Fig. 2. Positional variance diagram for the general 
ROMS population (Model 1). The maximum- 
likelihood sequence of abnormality is shown on the 
y-axis (top to bottom). Colour intensity in each row 
indicates positional variance: the darker the colour, 
the higher the confidence of the event position across 
1000 bootstraps (capped at 500 for visualisation). The 
biomarker ordering reflects the sequence obtained 
from fitting all subjects. EC = eigenvector centrality; 
EDSS: expanded disability status scale; FA: fractional 
anisotropy as a measure for microstructural WM tract 
changes; MUCCA: mean upper cervical cord area.   
Fig. 3. Patient staging for Model 1 (ROMS). Top: Staging of HC and ROMS 
subjects within the 21 disease stages. Bottom: Boxplot of staging indicating 
median (solid red line) and mean (dashed green line) of the groups. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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atrophy being a driving factor in disability worsening (Eshaghi et al., 
2018). The insula appears to be the earliest event but the considerable 
uncertainty suggests variability between individuals. 
Changes of the MUCCA measurement appear earlier and FA changes 
of the corticospinal tract appear later with respect to Model 1. This 
ostensibly contradictory finding could be interpreted such that initial 
damage of the corticospinal tract already occurred in patients with low 
disability (i.e. first event in the progression from HC to MS) and more 
severe damage (i.e. spinal cord atrophy) will become apparent later. At 
the same time the cord area is not strongly affected initially but changes 
become more detectable after MS onset has occurred as indicated by 
previous studies that have shown the relevance of spinal cord atrophy in 
explaining long-term disability (Daams, 2014; Lukas et al., 2015). 
The thalamus is broadly involved in cognitive and sensorimotor 
functions (Tewarie, 2015), which could explain the very early position 
in Model 1 and an early position in Model 2, and can be interpreted as a 
further increase in abnormality alongside the increase in disability. 
MS lesions appear to become significant towards the cortex as 
disability progresses, i.e. first in the periventricular white matter, then in 
the deep WM and finally closer to the cortex, which is in line with other 
studies showing a larger lesion load around the ventricles with fewer 
lesions juxtacortically (Rossi et al., 2012; Giorgio et al., 2013). It should 
be noted, however, that this study does not include measurements of 
cortical lesions, which needs to be addressed in subsequent studies. 
4.3. Model 3: Sequence of events in relapsing-onset multiple sclerosis as 
cognition declines 
In the dEBM sequence from CP to CI, early events were atrophy of the 
insula, hippocampus and spinal cord, as well as the increased functional 
centrality of the DMN. The early appearance of insular atrophy in this 
model is interesting in the light of previous studies showing the fastest 
volume loss in these areas in patients with SPMS (Eshaghi et al., 2018; 
Liu, 2014). We infer that these volume changes are an early event in the 
general MS population, confirmed by their respective positioning in a 
previous EBM study sequence (Eshaghi et al., 2018). 
A meaningful comparison of the functional centrality of networks is 
impeded by the exclusion of the basal ganglia and sensorimotor network 
biomarkers from the model due to statistically indistinguishable 
Fig. 4. Positional variance diagram for the progres-
sion from low to high disability in ROMS patients 
(Model 2). The maximum-likelihood sequence of ab-
normality is shown on the y-axis (top to bottom). 
Colour intensity in each row indicates positional 
variance: the darker the colour, the higher the confi-
dence of the event position across 1000 bootstraps 
(capped at 500 for visualisation). The biomarker 
ordering reflects the sequence obtained from fitting 
all subjects. EC = eigenvector centrality; EDSS: 
expanded disability status scale; FA: fractional 
anisotropy as a measure for microstructural WM tract 
changes; MUCCA: mean upper cervical cord area.   
Fig. 5. Patient staging for Model 2 (disability). Top: Staging of subjects with 
different levels of disability within the 25 disease stages. Bottom: Boxplot of 
staging indicating median (solid red line) and mean (dashed green line) of the 
groups. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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biomarker distributions between CP and CI groups, indicating that these 
have limited relevance to cognitive decline in MS. However, the 
increased functional centrality of the DMN was an early event in both 
model 2 and 3 suggesting that abnormality of DMN functional centrality 
could be an early indication of future cognitive and physical decline, as 
has been suggested extensively in MS literature (Eijlers et al., 2017; 
Schoonheim et al., 2015). 
The interpretation and relevance of the early positioning of MUCCA 
in the cognitive model is difficult to understand but might reflect the 
overlap between patients with CI and patients with increased physical 
disability (64% of patients with CI in this cohort also have more severe 
physical disability; see also Table 2 and 3 and Fig. 1). Lesion events 
appear in direct succession and the positional variance diagram (Fig. 6) 
indicates that abnormal lesion volumes occur in all three locations 
roughly at the same time, indicating that other measures such as atrophy 
and brain function are more important for cognition. 
Though thalamic atrophy has been associated with cognitive decline 
and disease progression (Schoonheim et al., 2012), it appears relatively 
later (mid-sequence) than expected in the dEBM sequence. This could be 
the result of a floor-effect as there is already thalamic atrophy present in 
CP patients (Henry, 2008) and further changes arise late in the pro-
gression from CP to CI. Microstructural WM changes appear late in 
model 3, which is consistent with model 2 and could imply that these 
measures reflect advanced stages of disease progression. A previous 
study showed that only CI patients with atrophy had microstructural 
WM changes and CP patients without atrophy did not have WM tract 
abnormalities (Eijlers et al., 2018). Alternatively, the order in which 
different tracts become abnormal varies and more tracts are affected 
with advanced disease (Huang et al., 2018). 
4.4. Considerations regarding features in the models 
White matter lesions are a sensitive indicator for MS diagnosis 
(Thompson, 2018) and are used extensively in daily clinical practice. We 
analysed lesion locations at three depths, with the inner band including 
the lesions close to the ventricles, the outer band including those close to 
the cortex, and the intermediate deep WM lesions in between (Pardini 
et al., 2016). While this definition is not as stringent as the clinically 
used stratification into periventricular, juxtacortical and deep lesions, it 
Fig. 6. Positional variance diagram for the progres-
sion in ROMS patients as cognition declines (Model 
3). The maximum-likelihood sequence of abnormality 
is shown on the y-axis (top to bottom). Colour in-
tensity in each row indicates positional variance: the 
darker the colour, the higher the confidence of the 
event position across 1000 bootstraps (capped at 500 
for visualisation). The biomarker ordering reflects the 
sequence obtained from fitting all subjects. EC =
eigenvector centrality; EDSS: expanded disability 
status scale; FA: fractional anisotropy as a measure for 
microstructural WM tract changes; MUCCA: mean 
upper cervical cord area.   
Fig. 7. Patient staging for Model 3 (cognition). Top: Staging of subjects with 
different levels of cognitive abilities within the 17 disease stages. Bottom: 
Boxplot of staging indicating median (solid red line) and mean (dashed green 
line) of the groups. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
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is a useful approximation that can be derived in a consistent and data- 
driven fashion. Infratentorial lesions were only present in a small sub-
set of patients and were therefore discarded from further analysis 
despite their involvement in clinical disability. Although minor 
(vascular) WM lesions could be present in controls, these lesions could 
not be included due to the lack of FLAIR imaging in controls. As such, in 
the analysis of general ROMS progression, Model 1, we did not include 
lesions. However, lesions would be expected to occur very early in the 
MS sequence. MUCCA measurement was performed using SCT-PropSeg 
on 3DT1 head images, which may have reduced sensitivity to change 
compared to dedicated cervical cord imaging although several studies 
have shown good agreement between MUCCA derived from head and 
cervical images (Lukas et al., 2018; Liu, 2016). We note that the 
considerable positional variance in the estimated ordering means that 
the exact positions of events should be interpreted with caution. Addi-
tionally, the ordering does not imply causation. 
While we took care to include biomarkers of relevance to MS pa-
thology, many more candidate biomarkers could be included in the 
future. Features such as spinal cord lesions (Sombekke et al., 2013), 
cerebrospinal fluid alterations (Disanto, 2017), or (semi)quantitative 
MR measures of myelination such as magnetization transfer ratio (MTR) 
have been shown to be sensitive to the MS pathogenesis but were un-
available in this cohort. 
4.5. Study limitations 
MS is a heterogeneous disease with multiple concurrent disease 
processes, which are difficult to model, especially with limited data. As a 
consequence, some biomarkers show clear bimodal behaviour in the 
positional variance diagram (e.g., cingulate and insular atrophy in 
Model 1), which suggests different orderings for subgroups of our 
cohort. While this impedes interpretation of some results, we believe 
that it is an important finding. An alternative way to model heteroge-
neous trajectories is to use advanced data-driven subtyping models such 
as SuStaIn (Young, 2018), which could potentially identify clusters of 
subjects that share a differential sequence of events and hence model the 
disease progression in MS more reliably. However, this typically re-
quires a larger dataset than is available here. 
The effects of disease modifying treatment is very challenging to 
model due to the heterogeneity in the disease progression and the 
resulting treatment options. In general, we would expect a reduction of 
EDSS or lesion occurrence as these are the main outcome measures for 
clinical trials. In this study, this would lead to a change in group as-
signments, especially for Model 2, but we would not expect a strong 
effect on other biomarkers or their event sequence. A comparison of 
sequences obtained from treated and untreated patients, as well as the 
effect of a complex statistical correction for treatment effects, should be 
performed in an independent and sufficiently large cohort. 
EBM provides a temporal ordering of biomarker abnormality, but no 
actual information about time as the intervals between subsequent 
events are not linear; this means that the division into late and early 
events can only be interpreted relative to other markers within the 
overall disease course. A combination of EBM-type models with longi-
tudinal data and survival models, however, could give an estimate of the 
timescales of disease progression (Young et al., 2014; Venkatraghavan 
et al., 2019). 
5. Conclusion 
This study has revealed the sequence of observable (biomarker) 
changes in brain structure, function, and cognition in the progression of 
ROMS, including specific sequences associated with disability wors-
ening and cognitive decline. In general, changes in GM volume, espe-
cially of the thalamus, insula, hippocampus and cerebellum were the 
earliest events in MS and MS-related physical disability and cognitive 
decline, which also showed strong involvement of default-mode 
dysfunction. Microstructural changes in WM tracts were predomi-
nantly late events, which deserves further investigation as it appears to 
contradict the early occurrence of focal white matter lesions in many 
tracts, possibly indicating that overall tract integrity is maintained for a 
longer period of time. The relatively high uncertainty could be reduced 
using advanced models taking into account multiple concurrent disease 
trajectories within one cohort. Future research should also include pa-
tients soon after first symptoms arise (i.e., CIS) to determine the earliest 
disease pathologies in MS with high certainty. 
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